Literature DB >> 15150818

A report from the international consensus on diagnosing and treating the infected diabetic foot.

Benjamin A Lipsky1.   

Abstract

In persons with diabetes, foot infection, that is, invasion and multiplication of microorganisms in tissues accompanied by tissue destruction or a host inflammatory response, usually begins with skin trauma or ulceration 1. While most foot infections remain superficial, they can spread to subcutaneous tissues, including muscle, joints, and bone. Many diabetic foot ulcers eventuate in an amputation; infection plays a role in approximately 60% of cases 2-4. Neuropathy is the main factor leading to skin breaks, while arterial perfusion largely affects infection outcome. Among the factors predisposing diabetic patients to foot infections are ill-defined immunological perturbations 56; foot anatomy may foster proximal spread of infection and ischemic necrosis 78. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150818     DOI: 10.1002/dmrr.453

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  49 in total

1.  Does dermal thermometry predict clinical outcome in diabetic foot infection? Analysis of data from the SIDESTEP* trial.

Authors:  David G Armstrong; Benjamin A Lipsky; Adam B Polis; Murray A Abramson
Journal:  Int Wound J       Date:  2006-12       Impact factor: 3.315

2.  One small step for diabetic podopathy.

Authors:  W Jeffcoate
Journal:  Diabetologia       Date:  2008-02       Impact factor: 10.122

3.  Tracking Anti-Staphylococcus aureus Antibodies Produced In Vivo and Ex Vivo during Foot Salvage Therapy for Diabetic Foot Infections Reveals Prognostic Insights and Evidence of Diversified Humoral Immunity.

Authors:  Irvin Oh; Gowrishankar Muthukrishnan; Mark J Ninomiya; James D Brodell; Benjamin L Smith; Charles C Lee; Steven R Gill; Christopher A Beck; Edward M Schwarz; John L Daiss
Journal:  Infect Immun       Date:  2018-11-20       Impact factor: 3.441

4.  Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.

Authors:  Jeroen P Jansen; Ritesh Kumar; Yehuda Carmeli
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 5.  MRSA and diabetic foot wounds: contaminating or infecting organisms?

Authors:  Frank L Bowling; Edward B Jude; Andrew J M Boulton
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

6.  Primarily non-surgical management of osteomyelitis of the foot in diabetes.

Authors:  F L Game; W J Jeffcoate
Journal:  Diabetologia       Date:  2008-04-03       Impact factor: 10.122

Review 7.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 8.  The treatment of diabetic foot infections: focus on ertapenem.

Authors:  Michael Edmonds
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

9.  Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.

Authors:  Mao Mao An; Zui Zou; Hui Shen; Jun Dong Zhang; Meng Li Chen; Ping Liu; Rui Wang; Yuan Ying Jiang
Journal:  BMC Infect Dis       Date:  2009-12-02       Impact factor: 3.090

10.  Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers.

Authors:  Christopher Yates; Kerry May; Thomas Hale; Bernard Allard; Naomi Rowlings; Amy Freeman; Jessica Harrison; Jane McCann; Paul Wraight
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.